San Francisco, CA, United States of America

Darryl Kato

This inventor holds 46 USPTO granted patents and 28 published patent applications, plus 11 CIPO patents and 22 EPO patents, primarily in Antiviral Compounds. Top assignees: Gilead Sciences, Inc., Gilead Pharmasset LLC. Active years: 2012-2025.

USPTO Granted Patents = 46 

% Patents Active = 97.8

 

 

Average Co-Inventor Count = 12.6

ph-index = 12

Forward Citations = 410(Granted Patents)


Location History:

  • Foster City, CA (US) (2012)
  • San Francisco, CA (US) (2013 - 2024)

Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
HIV Inhibitor Compounds
KRAS G12D Modulating Compounds
MCL1 Inhibitors
Capsid Inhibitors
Antiviral Compounds
Hepatitis C Virus Inhibitors
Syk Inhibitors
Therapeutic Compounds
Substituted Pyrrolidines
Therapeutics
Inhibitors of Hepatitis B
Synthesis of Antiviral Compounds
46 patents (USPTO):Explore Patents

Title: The Innovative Mind of Darryl Kato

Introduction: Darryl Kato, a visionary inventor based in San Francisco, CA, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Darryl Kato holds several patents in the realm of artificial intelligence and renewable energy technologies, showcasing his commitment to creating a sustainable future.

Career Highlights: With a career spanning over two decades, Darryl Kato has worked with leading tech companies to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Darryl Kato has collaborated with top researchers, engineers, and scientists to bring his innovative ideas to life, fostering a culture of creativity and excellence.

Conclusion: Darryl Kato's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…